ID

16463

Description

Safety and Efficacy Clinical Study of SNS-595 for Second-Line Therapy in Patients With Advanced NSCLC; ODM derived from: https://clinicaltrials.gov/show/NCT00252382

Link

https://clinicaltrials.gov/show/NCT00252382

Keywords

Versions (1)
  1. 7/17/16 7/17/16 -
Uploaded on

July 17, 2016

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Carcinoma, Non-Small-Cell Lung NCT00252382

English

Eligibility Carcinoma, Non-Small-Cell Lung NCT00252382

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
able to understand and willing to sign a written informed consent document
Description

Written informed consent

Data type

boolean

Alias
UMLS CUI [1]
C0021430
patients who have recurrent or metastatic nsclc, who have failed initial therapy with a platinum-containing regimen and have not received any second-line therapy (adjuvant therapy is acceptable if it was completed greater than or equal to 12 months before the cancer recurrence)
Description

NSCLC

Data type

boolean

Alias
UMLS CUI [1,1]
C0007131
UMLS CUI [1,2]
C0438286
measurable disease
Description

Measurable disease

Data type

boolean

Alias
UMLS CUI [1]
C1513041
eastern cooperative oncology group (ecog) performance status score of 0 or 1
Description

ECOG

Data type

boolean

Alias
UMLS CUI [1]
C1520224
laboratory values within the normal or reasonable reference range as specified by the protocol
Description

laboratory values

Data type

boolean

Alias
UMLS CUI [1]
C0022885
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
prior exposure to sns-595
Description

prior exposure to sns-595

Data type

boolean

Alias
UMLS CUI [1]
C1541378
pregnant or breastfeeding
Description

pregnant or breastfeeding

Data type

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
women of childbearing potential or male partners of women of childbearing potential unwilling to use an approved, effective means of contraception according to the institution's standards
Description

childbearing potential

Data type

boolean

Alias
UMLS CUI [1,1]
C3831118
UMLS CUI [1,2]
C0700589
other active malignancies or other malignancies within the past 12 months except non-melanoma skin cancer, cervical intraepithelial neoplasia or prostatic intraepithelial neoplasia
Description

Malignancies

Data type

boolean

Alias
UMLS CUI [1]
C0006826
brain metastases, if present, without radiologic evidence of progressive disease for at least 3 months after completion of therapy
Description

Brain metastases

Data type

boolean

Alias
UMLS CUI [1]
C0220650
myocardial infarction, cerebrovascular accident/transient ischemic attack (tia) or thromboembolic event (deep vein thrombosis or pulmonary embolus) within 6 months before the first sns-595 dose
Description

myocardial infarction, cerebrovascular accident/transient ischemic attack (tia) or thromboembolic event

Data type

boolean

Alias
UMLS CUI [1]
C0027051
UMLS CUI [2]
C0038454
UMLS CUI [3]
C0007787
UMLS CUI [4]
C0040038
requires kidney dialysis (hemodialysis or peritoneal)
Description

Renal dialysis

Data type

boolean

Alias
UMLS CUI [1]
C0011946
prior chemotherapy, investigational agents, or radiation therapy within 28 days before cycle 1 day 0; however, nitrosoureas and mitomycin are not permitted for at least 42 days before cycle 1 day 0
Description

prior chemotherapy, investigational agents, or radiation therapy

Data type

boolean

Alias
UMLS CUI [1]
C0392920
UMLS CUI [2]
C0013230
UMLS CUI [3]
C1522449
in patients with toxicities caused by prior cancer therapy, those toxicities must have returned to less than or equal to grade 1, with the exception of alopecia
Description

Toxicity

Data type

boolean

Alias
UMLS CUI [1]
C0013221
prior pelvic radiation therapy or radiation to greater than or equal to 25% of bone marrow reserve (prior palliative radiation is permitted as long as it does not exceed 25% of bone marrow reserve)
Description

Radiation therapy

Data type

boolean

Alias
UMLS CUI [1]
C1522449
any other medical, psychological, or social condition that, in the opinion of the principal investigator, would contraindicate the patient's participation in the clinical trial due to safety concerns or compliance with study procedures
Description

other medical, psychological, or social condition

Data type

boolean

Alias
UMLS CUI [1,1]
C1321605
UMLS CUI [1,2]
C0439801
UMLS CUI [1,3]
C0009488
Back to the top of the page

Similar models

Eligibility Carcinoma, Non-Small-Cell Lung NCT00252382

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Written informed consent
Item
able to understand and willing to sign a written informed consent document
boolean
C0021430 (UMLS CUI [1])
NSCLC
Item
patients who have recurrent or metastatic nsclc, who have failed initial therapy with a platinum-containing regimen and have not received any second-line therapy (adjuvant therapy is acceptable if it was completed greater than or equal to 12 months before the cancer recurrence)
boolean
C0007131 (UMLS CUI [1,1])
C0438286 (UMLS CUI [1,2])
Measurable disease
Item
measurable disease
boolean
C1513041 (UMLS CUI [1])
ECOG
Item
eastern cooperative oncology group (ecog) performance status score of 0 or 1
boolean
C1520224 (UMLS CUI [1])
laboratory values
Item
laboratory values within the normal or reasonable reference range as specified by the protocol
boolean
C0022885 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
prior exposure to sns-595
Item
prior exposure to sns-595
boolean
C1541378 (UMLS CUI [1])
pregnant or breastfeeding
Item
pregnant or breastfeeding
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
childbearing potential
Item
women of childbearing potential or male partners of women of childbearing potential unwilling to use an approved, effective means of contraception according to the institution's standards
boolean
C3831118 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
Malignancies
Item
other active malignancies or other malignancies within the past 12 months except non-melanoma skin cancer, cervical intraepithelial neoplasia or prostatic intraepithelial neoplasia
boolean
C0006826 (UMLS CUI [1])
Brain metastases
Item
brain metastases, if present, without radiologic evidence of progressive disease for at least 3 months after completion of therapy
boolean
C0220650 (UMLS CUI [1])
myocardial infarction, cerebrovascular accident/transient ischemic attack (tia) or thromboembolic event
Item
myocardial infarction, cerebrovascular accident/transient ischemic attack (tia) or thromboembolic event (deep vein thrombosis or pulmonary embolus) within 6 months before the first sns-595 dose
boolean
C0027051 (UMLS CUI [1])
C0038454 (UMLS CUI [2])
C0007787 (UMLS CUI [3])
C0040038 (UMLS CUI [4])
Renal dialysis
Item
requires kidney dialysis (hemodialysis or peritoneal)
boolean
C0011946 (UMLS CUI [1])
prior chemotherapy, investigational agents, or radiation therapy
Item
prior chemotherapy, investigational agents, or radiation therapy within 28 days before cycle 1 day 0; however, nitrosoureas and mitomycin are not permitted for at least 42 days before cycle 1 day 0
boolean
C0392920 (UMLS CUI [1])
C0013230 (UMLS CUI [2])
C1522449 (UMLS CUI [3])
Toxicity
Item
in patients with toxicities caused by prior cancer therapy, those toxicities must have returned to less than or equal to grade 1, with the exception of alopecia
boolean
C0013221 (UMLS CUI [1])
Radiation therapy
Item
prior pelvic radiation therapy or radiation to greater than or equal to 25% of bone marrow reserve (prior palliative radiation is permitted as long as it does not exceed 25% of bone marrow reserve)
boolean
C1522449 (UMLS CUI [1])
other medical, psychological, or social condition
Item
any other medical, psychological, or social condition that, in the opinion of the principal investigator, would contraindicate the patient's participation in the clinical trial due to safety concerns or compliance with study procedures
boolean
C1321605 (UMLS CUI [1,1])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial